dr donna h ryan glp 1 CRS 2017: Cardiometabolic Disease and Obesity: A Q&A With Donna H Ryan

Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist increasingly prescribed for weight loss, is generally well tolerated but may have underrecognized gastrointestinal complications

Thankfully, there are new weapons in the

Learn about drug interactions with immunosuppressants, monitoring requirements, NHS guidance, and emerging clinical evidence for kidney, liver, and heart transplant recipients.

A Re/Insurance View Of GLP-1s (Glucagon-Like Peptide 1 Receptor Agonists) October 2025 Share (3 Minute Read) Share this page Close

They have a tremendous amount of disease burden, []

Adults with type 2 diabetes and cancer who used a GLP-1 had a lower risk for death and hospitalization compared with adults who used metformin, according to findings published in The Journal of Clinical Endocrinology &amp